Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYCNNASDAQ:FTSVNASDAQ:GERNNASDAQ:SYRSNASDAQ:TORC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$2.87+3.6%$3.09$1.75▼$6.75$7.78M1.843,170 shs156 shsFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AGERNGeron$3.50-2.2%$2.83$1.64▼$4.05$1.91B0.6211.07 million shs5.97 million shsSYRSSyros Pharmaceuticals$5.01-1.2%$6.13$2.09▼$8.17$133.92M1.74212,639 shs38,837 shsTORCresTORbio$1.88-10.7%$12.16$0.86▼$10.50$68.35M2.431.15 million shs1.48 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+2.17%-12.92%-6.60%-4.71%-49.25%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%GERNGeron+2.29%-2.72%+9.82%+65.74%+47.93%SYRSSyros Pharmaceuticals-1.36%-0.78%-20.78%-23.30%+69.00%TORCresTORbio0.00%-4.11%-4.55%-14.98%-65.63%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)See this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AN/AN/AN/AGERNGeron3.2775 of 5 stars3.53.00.01.31.41.70.6SYRSSyros Pharmaceuticals3.7954 of 5 stars3.51.00.04.31.13.30.6TORCresTORbioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion TherapeuticsN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AGERNGeron3.00Buy$5.3352.38% UpsideSYRSSyros Pharmaceuticals3.00Buy$14.33186.09% UpsideTORCresTORbioN/AN/AN/AN/ACurrent Analyst RatingsLatest FTSV, CYCN, GERN, SYRS, and TORC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.004/3/2024SYRSSyros PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.004/1/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.002/28/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$1.62M4.80N/AN/A$4.62 per share0.62FTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70GERNGeron$240K7,975.19N/AN/A$0.46 per share7.61SYRSSyros Pharmaceuticals$9.94M13.47N/AN/A$0.79 per share6.34TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)FTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/AGERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)SYRSSyros Pharmaceuticals-$164.57M-$5.76N/AN/AN/A-1,656.34%-227.91%-75.60%5/8/2024 (Estimated)TORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/ALatest FTSV, CYCN, GERN, SYRS, and TORC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023SYRSSyros Pharmaceuticals-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 million2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A3.853.85FTSVForty SevenN/A14.8114.81GERNGeron0.143.163.16SYRSSyros Pharmaceuticals2.073.953.95TORCresTORbioN/A20.6920.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%FTSVForty Seven71.77%GERNGeron73.71%SYRSSyros Pharmaceuticals91.47%TORCresTORbio46.19%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics13.10%FTSVForty Seven37.40%GERNGeron3.10%SYRSSyros Pharmaceuticals10.45%TORCresTORbio11.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataFTSVForty Seven5748.16 millionN/ANot OptionableGERNGeron141546.87 million529.92 millionOptionableSYRSSyros Pharmaceuticals6826.73 million23.94 millionOptionableTORCresTORbioN/A36.45 millionN/ANot OptionableFTSV, CYCN, GERN, SYRS, and TORC HeadlinesSourceHeadlineJohn Flynnfleetowner.com - April 24 at 4:23 PMAdicet Bio Inc (ACET)investing.com - January 30 at 1:54 PMTargeting the biology of aging with mTOR inhibitors - Nature.comnews.google.com - May 4 at 10:20 PMPARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLivenews.google.com - March 17 at 7:14 PMMichelle Chaka Joins Torc as Senior Vice President, Safety and Regulatoryfinance.yahoo.com - February 24 at 7:08 PMTorc names regulatory, safety SVPvirginiabusiness.com - February 24 at 7:08 PMGlobal AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPRnews.google.com - February 8 at 10:13 AMPhenotypic Presentations and the Management of Moderate to ... - Healionews.google.com - January 31 at 2:37 PMAerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.comnews.google.com - January 23 at 3:41 PMAerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswirenews.google.com - January 23 at 8:44 AMTinOne Resources Inc. (TORC.V)finance.yahoo.com - January 10 at 8:39 AMresTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities Newsnews.google.com - December 16 at 11:48 PMresTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities Newsnews.google.com - December 12 at 10:01 PMBrian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.Technologynews.google.com - November 3 at 9:25 PMTORC Investments, LLCgwinnettdailypost.com - October 6 at 9:57 AMCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbesforbes.com - September 19 at 2:52 PMFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business Journalsbizjournals.com - September 12 at 7:31 PMCellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPRopenpr.com - September 6 at 7:33 AMFor preventing aging, some decades old drugs? - BioWorld Onlinebioworld.com - July 18 at 10:42 PMForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comstreetinsider.com - July 8 at 2:10 AMTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.comgurufocus.com - June 21 at 9:11 PMThe Best Hand Creams - Don't Waste Your Moneydontwasteyourmoney.com - June 18 at 1:34 PMTime Passages: Bruce Goldsmith out at Jim Wilson's gene therapy biotech; Flagship reveals Michael Severino's CEO gig - Endpoints Newsendpts.com - June 3 at 11:42 PMTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - KULR-TVkulr8.com - June 3 at 11:42 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Forty SevenNASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.GeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Syros PharmaceuticalsNASDAQ:SYRSSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.resTORbioNASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.